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Abstract
Background: After promising results in experimental stroke, normobaric (NBO) or hyperbaric oxygenation (HBO)
have recently been discussed as co-medication with tissue plasminogen activator (tPA) for improving outcome.
This study assessed the interactions of hyperoxia and tPA, focusing on survival, early functional outcome and
blood-brain barrier (BBB) integrity following experimental stroke.
Methods: Rats (n = 109) underwent embolic middle cerebral artery occlusion or sham surgery. Animals were
assigned to: Control, NBO (60-minute pure oxygen), HBO (60-minute pure oxygen at 2.4 absolute atmospheres),
tPA, or HBO+tPA. Functional impairment was assessed at 4 and 24 hours using Menzies score, followed by
intravenous application of FITC-albumin as a BBB permeability marker, which was allowed to circulate for 1 hour.
Further, blood sampling was performed at 5 and 25 hours for MMP-2, MMP-9, TIMP-1 and TIMP-2 concentration.
Results: Mortality rates did not differ significantly between groups, whereas functional improvement was found for
NBO, tPA and HBO+tPA. NBO and HBO tended to stabilize BBB and to reduce MMP-2. tPA tended to increase BBB
permeability with corresponding MMP and TIMP elevation. Co-administered HBO failed to attenuate these early
deleterious effects, independent of functional improvement.
Conclusions: The long-term consequences of simultaneously applied tPA and both NBO and HBO need to be
addressed by further studies to identify therapeutic potencies in acute stroke, and to avoid unfavorable courses
following combined treatment.
Background
The repeated translational failures of preclinical
approaches in acute ischemic stroke necessitate a more
complex perspective of tissue salvaging and regeneration
in experimental research [1], involving functional key-
structures such as the blood-brain barrier (BBB) with the
associated ‘neurovascular unit’ [2-5]. Thromboembolic
models are considered to provide best comparability to
the human pathophysiology, thus being of increasing
interest [5,6]. Along with the growing knowledge on time-
dependent BBB changes [7,8], matrix metalloproteinases
(MMPs) and their inhibitors (TIMPs) were proposed as
mediators with deleterious effects in early phases, but also
regenerative properties in subsequent phases [9,10]. The
application of oxygen under normobaric (NBO) or hyper-
baric (HBO) conditions was shown to be beneficial in
experimental studies by decreasing infarct size, functional
impairment, hemorrhagic transformation, and early MMP
response leading to BBB stabilization [11-17]. Recently,
hyperoxia was discussed as co-medication to tissue plasmi-
nogen activator (tPA) [17,18], which even results in clini-
cal improvement [19], but is also known for MMP
activation and BBB breakdown with possible hemorrhagic
transformation [20-22]. Hence, hyperoxia might attenuate
deleterious tPA effects and improve the clinical outcome
[18]. Our group previously found that simultaneous treat-
ment with tPA and HBO may have detrimental effects on
long-term outcome in rats, possibly by influencing BBB
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aimed on interacting effects of hyperoxia and tPA with
special emphasis on survival, early functional outcome,
BBB integrity and related mediators in a translational rele-
vant setting after thromboembolic stroke in rats.
Methods
Experimental design and interventions
The experimental protocol involving animals was
approved by local authorities [Regierungspräsidium Leip-
zig, Tierversuchsvorhaben (TVV) 02/09] and has been
conducted according to the European Communities
Council Directive (86/609/EEC). Male Wistar rats (mean
weight 316.2 g), provided by Charles River (Sulzfeld, Ger-
many), underwent right-sided middle cerebral artery
occlusion (MCAO; n = 105) or sham operation (n = 4),
as described below. Thirteen animals died during surgery
and 4 animals were excluded from the study due to
minor functional impairment (Menzies score 0-1) indi-
cating insufficient cerebral ischemia, as specified pre-
viously. Finally, 92 animals were consecutively assigned
to sham surgery (n = 4), MCAO control (n = 17), NBO
(n = 18), HBO (n = 16), tPA (n = 19), or HBO+tPA (n =
18). Treatment was initiated 2 hours after ischemia
onset: The NBO group received 60 minutes of normoba-
ric pure oxygen in a hyperbaric chamber (Sayers/Hebold,
Cuxhaven, Germany), the HBO group underwent 60
minutes (plus compression/decompression) of 100% O2
at 2.4 absolute atmospheres (ATA). tPA-treated animals
received 9 mg/kg bodyweight tPA (Actilyse, Boehringer,
Ingelheim, Germany) intravenously over 30 minutes. The
HBO+tPA group simultaneously received tPA and HBO
beginning at 2 hours. Functional impairment was
assessed after surgery (baseline) and 4- or rather 24-hour
observation period post MCAO, iimmediately followed
by fluorescein isothiocyanate (FITC)-albumin injection
via a femoral vein (20 mg/1 mL saline; Sigma, Tauf-
kirchen, Germany) for visualization of BBB permeability.
After usually 1 hour of circulation, animals were sacri-
ficed in deep narcosis. Blood samples were drawn trans-
cardially, followed by perfusion with saline and 4%
paraformaldehyde in phosphate-buffered saline (PFA).
Brains were removed from skull, immersed in the same
fixative for 24 hours and equilibrated in 30% buffered
sucrose. All study endpoints were defined prior to the
first animal enrollment.
Surgical procedure
MCAO was induced using an embolic model according
to Zhang et al. [24] with minor modifications as
described previously [23]. Briefly, a polyethylene (PE)
tubing with tapered end was advanced from an incision
of the external carotid artery (ECA) into the internal
carotid artery, reaching the origin of the middle cerebral
artery. A weight-adapted blood clot (mean length 46
mm) was injected, followed by catheter removal and
ligation of the ECA stump. The sham operation was
performed in the same manner, including preparation of
cervical vessels, but without catheter insertion. In all
groups, PE tubes were inserted into the femoral vein for
tPA administration and the femoral artery for monitor-
ing heart rate, arterial pressure (Datex, Helsinki,
Finland), and obtaining blood samples (PaO2 and glu-
cose; ABL 700, Radiometer, Copenhagen, Denmark)
during surgery and after therapy. Animals were anesthe-
tized using 2-2.5% isoflurane (70% N2O/30% O2) during
surgery. Thereby, the body temperature was adjusted to
37.0°C using a thermostatically controlled heating pad
(Fine Science Tools, Heidelberg, Germany) with rectal
probe.
Assessment on mortality and functional impairment
The rate of premature death was recorded in each treat-
ment group during the observation period including
associated FITC-albumin injection. The Menzies score
was used to assess functional impairment [25], scaled
from 0 (no apparent deficits) up to 4 (spontaneous con-
tralateral circling).
Tissue preparation, imaging and quantification of BBB
permeability
The visualization technique of BBB impairment after in
vivo application of FITC-albumin as permeability marker
was described previously [26]. Briefly, 30 μm-thick serial
brain sections were cut coronally using a freezing micro-
tome. Ten series of sections per animal were stored in
0.1 mol/L Tris-buffered saline (TBS; pH 7.4) containing
sodium azide. After washing, sections were mounted on
fluorescence-free slides, air-dried and coverslipped with
Entellan in toluene (Merck, Darmstadt, Germany). Subse-
quent to a screening microscopy (Axioplan, Zeiss, Jena,
Germany) for identification of sections with the clearest
infarct presentation by FITC-albumin leakage, the neigh-
boring serial sections were blocked (TBS, 2% bovine
serum albumin, 0.3% Triton X-100 [TBS-BSA-T]), fol-
lowed by an enhancement of the green fluorescent signal
with carbocyanine (Cy)2-anti-FITC IgG (20 μg/mL TBS-
BSA-T; Jackson ImmunoResearch, West Grove, PA) for
long-term stabilization. Moreover, vascular membranes
were detected by SMI-71 (1:400; Emeryville, CA [27])
and Cy3-donkey-anti-mouse IgM (20 μg/mL TBS-BSA;
Jackson), colored in red. Finally, washing, mounting and
coverslipping were performed as described above. Fluor-
escence-based paravasal intensity of enhanced FITC-
albumin served as surrogate for BBB permeability, as
exemplarily shown in Figure 1, and was analyzed by a
blinded investigator. For this purpose, a fluorescence
microscope (Axioplan 2, Zeiss) with structured-light
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camera (ORCA-ER, Hamamatsu, Hamamatsu City,
Japan) and imaging software (Volocity 4.3, PerkinElmer,
Waltham, MA) was used. Routinely, 3 vessels in the
lesion-bordering zone with clearest leakage phenomena
were selected. Six measurements were performed for
each of the chosen vessels by using cylindrical region of
interests (ROIs; diameter 2 μm) with 9 confocal layers (z-
interval 0.5 μm) at each point, obtained at 40x magnifica-
tion using a water immersion objective (numerical aper-
ture 1.4), with further digital zoom if necessary. ROIs
were positioned intravasally (n = 3) and with distance of
approximately 2 μm from the vessel wall (n = 3). To con-
trol for any background staining, 1 corresponding vessel
in the contra-lesional hemisphere was identified by SMI-
71/Cy3 and paravasal space was measured by 3 ROIs in
the same manner. For all measurements the following
setup was applied: Exposure time 80 ms, gain 0, offset 0,
super grid quality, grid gain 3x, excitation Cy2 480 nm,
emission 527 nm, excitation Cy3 545 nm, emission 610
nm. The obtained mean intensity within the ROIs was
used for further processing. Finally, means of 3 ipsi-
lesional vessels and 1 contra-lesional vessel were calcu-
lated and subtracted for total leakage. Furthermore, a
surrogate for BBB integrity was calculated as extra-/intra-
vasal ratio on the affected hemisphere indicating the
leakage proportion. For optimal presentation, micro-
graphs of fluorescence labeling were obtained using a 510
Meta laser scanning microscope (Zeiss), equipped with
an argon laser (488 nm) for the excitation of Cy2, and
two helium-neon lasers for the excitation of Cy 3 (543
nm). For the detection of emitted spectra, the following
band-pass filters were used: 500-530 nm for Cy2 (green),
and 565-615 nm for Cy3 (red). The original images were
processed with Adobe Photoshop 7.0 (Adobe Systems
Inc., Mountain View, CA). Thereby, brightness, contrast
and sharpness of the final pictures were slightly modified.
Measuring BBB-related serum markers
Samples were allowed to clot, and then centrifuged and
finally stored up to -80°C. After thawing, MMP-2,
MMP-9, TIMP-1 and TIMP-2 concentrations were
determined in a blinded fashion by using enzyme-linked
immunosorbent assays (USCN, Wuhan, China;
E90100Ra/E90553Ra/E90552Ra/E90128Ra). The mini-
mum detectable dose, which was differentiable from
zero (as listed in the instruction manual), was utilized
for values under the minimum or with uncertain calcu-
lation at the lower standard curve.
Statistical analysis
All calculations were performed with SPSS Vers. 18.0
(SPSS Inc, an IBM Company, Chicago, IL). One-way
analysis of variance (ANOVA) was applied for inter-
g r o u pd i f f e r e n c e sa tas i n g l et i m ep o i n t ,f o l l o w e db y
the Duncan test considering multiple means. For intra-
group testing at different time points, Wilcoxon-
Mann-Whitney and Kolmogorov-Smirnov tests were
performed. Percentage rates were verified using the
Chi-square test with additional Monte Carlo simula-
tion (confidence interval = 99%, samples = 10,000),
ensuring exact testing. Pearson correlations were
applied for interrelations. A P < 0.05 was considered as
statistically significant.
Figure 1 Demonstration of enhanced FITC-albumin measurement as BBB leakage marker at 5 and 25 hours after embolic stroke in
rats by confocal laser scanning micrographs. (A), representative striatal ischemia-related leakage of Cy2-enhanced FITC-albumin at 5×
magnification in a NBO-treated animal at 5 hours. (B), enhanced FITC-albumin in ischemic border zone at 10× magnification showing impaired
vascular structures with leakage phenomena. (C), para- and intravasal inserted region of interests at 63× magnification. (D), 63× magnification of
the corresponding area at the non-ischemic hemisphere: Detection of FITC-albumin background staining combined with Cy3-immunolabeling of
SMI-71 for vessel localization. Absent leakage indicates BBB integrity. Scale bars: in A = 500 μm, in B = 100 μm, and in D = 25 μm.
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Physiological parameters were similar between groups
with exception of weight (slightly increased in sham-
and tPA-treated animals), and marginal differences in
temperature, mean arterial pressure and PaO2 -o v e r a l l
indicating no major group differences (Table 1). As
expected for this model, ischemia predominantly
occurred in the proximal section of the middle cerebral
artery territory with varying infarct sizes as indicated by
FITC-albumin leakage.
Mortality and early functional impairment
Premature death occurred in a total of 8 animals
(8.7%). The distribution according to the treatment
groups is shown in Figure 2A, and was not statistically
significant (Chi-square, P = 0.617; Monte Carlo, P =
0.678). As expected, no functional impairment was
found in sham-assigned animals. Figure 2B indicates
the course of functional impairment depending on
treatment. At baseline and 4 hours, impairment did
not differ between the groups (ANOVA, P =0 . 0 7 3 ,
P = 0.437); at 24 hours differences were found
(ANOVA, P = 0.004) with superiority for NBO, tPA
and HBO+tPA compared with control and HBO (Dun-
can, P < 0.05). Regarding the time course, controls
showed a progressive functional impairment during the
first 24 hours (Wilcoxon-Mann-Whitney, P =0 . 0 4 4 ) ,
whereas improvement was noted for NBO, tPA and
Table 1 Physiological parameters
Sham Control NBO HBO tPA HBO+tPA ANOVA
mean ± SD mean ± SD mean ± SD mean ± SD mean ± SD mean ± SD F (P)
Weight (g) 357.8 ± 10.9 324.1 ± 45.6 304.3 ± 26.2 296.9 ± 26.5 334.8 ± 36.6 317.0 ± 17.5 4.6 (**)†
Duration of surgery (minutes) 63.8 ± 9.1 74.5 ± 25.5 66.6 ± 18.2 71.0 ± 22.8 68.3 ± 14.7 58.1 ± 12.6 1.5 (n.s.)
Temperature (°C)
Initial 37.5 ± 0.4 37.5 ± 0.4 37.6 ± 0.5 37.7 ± 0.3 37.5 ± 0.3 37.6 ± 0.5 0.7 (n.s.)
After catheter 37.6 ± 0.2 37.3 ± 0.3 37.2 ± 0.3 37.1 ± 0.4 37.2 ± 0.7 37.2 ± 0.4 0.9 (n.s.)
After clot injection 37.5 ± 0.0 37.4 ± 0.2 37.3 ± 0.3 37.2 ± 0.3 37.3 ± 0.7 37.1 ± 0.6 1.1 (n.s.)
End of surgery 37.6 ± 0.4 37.5 ± 0.3 37.2 ± 0.2 37.3 ± 0.3 37.4 ± 0.4 37.0 ± 0.5 3.6 (**)‡
After therapy n/a n/a 36.8 ± 0.8 37.3 ± 0.7 37.2 ± 0.8 36.9 ± 0.8 1.7 (n.s.)
Mean arterial pressure (mmHg)
After catheter 75.7 ± 3.5 82.9 ± 6.5 78.1 ± 8.4 77.8 ± 8.4 74.4 ± 9.0 79.9 ± 8.2 2.2 (n.s.)
After clot injection 72.5 ± 3.5 78.2 ± 6.3 73.3 ± 5.8 77.1 ± 9.0 72.4 ± 7.9 77.7 ± 11.8 1.5 (n.s.)
End of surgery 62.0 ± 3.0 75.3 ± 8.3 74.8 ± 13.2 79.1 ± 11.7 71.4 ± 7.2 81.9 ± 12.6 3.0 (*)§
After therapy n/a n/a 96.0 ± 15.5 86.9 ± 10.7 84.4 ± 12.9 86.9 ± 17.0 2.1 (n.s.)
Heart rate (per minute)
After catheter 206.7 ± 42.5 188.5 ± 17.5 189.3 ± 12.6 191.5 ± 21.8 197.0 ± 18.5 192.7 ± 26.9 0.7 (n.s.)
After clot injection 220.0 ± 49.5 194.5 ± 12.0 187.9 ± 17.0 203.1 ± 27.7 192.4 ± 21.7 203.9 ± 23.2 1.8 (n.s.)
End of surgery 220.0 ± 40.9 198.5 ± 12.3 200.6 ± 25.3 200.9 ± 22.2 192.8 ± 18.9 200.2 ± 19.0 1.0 (n.s.)
After therapy n/a n/a 203.1 ± 13.3 194.5 ± 13.0 204.2 ± 18.0 212.2 ± 21.7 2.7 (n.s.)
PaO2 (mmHg)
After catheter 97.4 ± 9.1 102.8 ± 13.7 104.2 ± 22.6 97.9 ± 14.5 98.6 ± 9.2 105.1 ± 12.9 0.7 (n.s.)
End of surgery 105.3 ± 12.3 114.1 ± 29.5 118.6 ± 19.9 108.5 ± 18.3 107.6 ± 13.8 114.7 ± 14.5 0.8 (n.s.)
After therapy n/a n/a 117.8 ± 23.9 118.4 ± 18.2 117.7 ± 13.6 149.8 ± 28.9 8.8 (***)II
Blood glucose (mmol/l)
After catheter 13.5 ± 1.7 10.5 ± 1.9 12.2 ± 2.3 11.8 ± 1.5 11.1 ± 2.5 11.4 ± 1.6 2.1 (n.s.)
End of surgery 13.2 ± 1.5 10.4 ± 1.9 11.8 ± 3.3 10.6 ± 1.6 11.2 ± 3.1 11.6 ± 2.4 0.9 (n.s.)
After therapy n/a n/a 9.2 ± 1.8 10.0 ± 1.8 8.8 ± 1.4 9.9 ± 1.5 2.2 (n.s.)
P: *<0.05, **<0.01, ***<0.001; Duncan test: †, sham/tPA > control/NBO/HBO/HBO+tPA; ‡, HBO+tPA < sham/control/HBO/tPA; §, sham < control/NBO/HBO/tPA/HBO
+tPA; II, HBO+tPA > NBO/HBO/tPA
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24 hours P = 0.044, tPA-baseline/24 hours P =0 . 0 2 3 ,
4/24 hours P = 0.039, HBO+tPA-baseline/4 hours P =
0.006, baseline/24 hours P = 0.048). No time-depen-
dent changes appeared in HBO-treated animals.
BBB permeability
FITC-albumin leakage was not observed in sham animals
(data not shown). In controls, total leakage declined from
5t o2 5h o u r s( F i g u r e3 A ) .C o n c e r n i n gt h et r e a t m e n t ,
total leakage differed at 5 hours (ANOVA, P = 0.046)
between tPA and NBO, as well as between tPA and HBO
+tPA (Duncan, P < 0.05 each). HBO tended to reduce
leakage, but this was not statistically significant. At 25
hours, no group-specific differences of total leakage
occurred (ANOVA, P = 0.413), whereas combined treat-
ment with HBO and tPA tended to increased leakage.
Concerning the time course, controls and NBO-treated
animals showed a significant reduction from initial
values, indicating dynamic properties of BBB integrity
(Kolmogorov-Smirnov, P = 0.022, P = 0.004).
Extra-/intravasal ratios (Figure 3B) did not differ
between treatment groups at either 5 or 25 hours
(ANOVA, P =0 . 0 9 7 ,P = 0.682). At 25 hours, oxygen
application (NBO or HBO) tended to have the lowest
leakage proportions, in contrast to worsened tPA- and
HBO+tPA-treated animals. Time-dependent changes were
solely found for NBO with a decreasing value (Kolmo-
gorov-Smirnov, P = 0.022). The leakage proportion of the
whole sample significantly correlated with functional
impairment at baseline and 4 hours (Pearson, r =0 . 3 9 1 ,
P =0 . 0 0 0 ,r =0 . 3 9 2 ,P = 0.001), but failed to correlate at
24 hours (Pearson, r = 0.186, P = 0.251).
BBB-related serum markers
As shown in Figure 4, significantly lower MMP-2 levels
were detected in sham animals at 5 hours as compared to
all other groups (ANOVA, P =0 . 0 1 2 ;D u n c a n ,P <0 . 0 5 ) .
At 25 hours, HBO resulted in decreased MMP-2 levels as
compared to tPA and HBO+tPA (ANOVA, P =0 . 0 0 1 ;
Duncan, P < 0.05). Concerning the time course, MMP-2
l e v e l sd e c r e a s e di nc o n t r o l s ,a n dN B O - ,H B O -a n dt P A -
treated animals (Kolmogorov-Smirnov, P =0 . 0 0 1 ,P =
0.001, P = 0.001, P =0 . 0 3 7 ) .A ss h o w ni nF i g u r e4 B ,n o
significant treatment-related differences occurred for
MMP-9 (ANOVA, 5 hours P = 0.316, 25 hours P =
0.554), but decreasing levels between 5 and 25 hours
w e r ef o u n di nc o n t r o l s ,H B O -a n dH B O + t P A - t r e a t e d
animals (Kolmogorov-Smirnov, P = 0.004, P =0 . 0 3 0 ,P =
0.004). For TIMP-1 (Figure 4C), tPA and HBO+tPA-
assigned animals revealed increased levels at 5 hours
compared to sham, control and NBO (ANOVA, P =
0.000; Duncan, P< 0.05). At 25 hours, HBO+tPA showed
the highest TIMP-1 levels, followed by tPA/sham and
HBO (ANOVA, P = 0.000; Duncan, P < 0.05). For HBO,
the TIMP-1 levels significantly declined between 5 and
25 hours (Kolmogorov-Smirnov, P =0 . 0 3 7 ) .T I M P - 2
(Figure 4D) demonstrated no treatment-specific differ-
ences at 5 hours (ANOVA, P = 0.388), but the co-admin-
istration of HBO and tPA led to increased TIMP-2 levels
at 25 hours as compared to HBO, control and sham
(ANOVA, P = 0.011; Duncan, P < 0.05). A TIMP-2
reduction between 5 and 25 hours was noted for
controls, HBO- and tPA-treated animals (Kolmogorov-
Smirnov, P = 0.001, P = 0.001, P = 0.007).
Discussion
For the first time, the present data provide insights into
complex BBB processes following hyperoxia, supplemen-
ted by testing HBO and tPA simultaneously. This study
focused on changes of BBB integrity in the early stages
following stroke due to their potential long-term rele-
vance. In consideration of translational aspects [5,6], an
embolic model was chosen and treatment initiated after
ischemia onset without preconditioning attempts.
Figure 2 Mortality rates (A) during observational period
depending on intervention. Sample size (sham/control/NBO/HBO/
tPA/HBO+tPA): 4/17/18/16/19/18. Time course of functional
impairment (B) depending on intervention. Sample size at baseline
(control/NBO/HBO/tPA/HBO+tPA): 17/18/16/19/18, at 4 hours: 11/11/
16/18/16, at 24 hours: 9/8/8/8/8. Bars: means, lines: standard errors,
P-value: *<0.05, **<0.01.
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groups, notably for the combined treatment with HBO
and tPA. This finding reinforced previous reports that
focused on additional NBO to tPA and provided com-
parable results when applied simultaneously [28], or
consecutively by starting with NBO [12,29]. Functional
impairment deteriorated in controls during first 24
hours emphasizing progressive stroke, contrary to signif-
icant improvement following NBO, tPA and HBO+tPA
treatment. Previous reports on the short-term beneficial
effects of tPA [23,28] are confirmed by the current data.
The surprising lack of HBO efficacy raises several ques-
tions such as those of the pressure used (2.4 ATA), pos-
sibly suboptimal to obtain beneficial effects, but chosen
due to well tolerability in patients with other diseases
(e.g., problem wounds). However, previous data on
hyperoxia in experimental stroke indicate efficacy predo-
minantly in transient versus permanent ischemia [13,17].
By investigating leakage phenomena on vascular struc-
tures at 2 different time points, mechanisms of ischemia-
induced BBB damage were addressed quantitatively.
Previous studies investigated extravasation mainly by
quantifying Evans Blue [7,30,31], sodium fluorescein [16]
or FITC-dextran [32] directly, or even by gadolinium-
enhanced magnetic resonance imaging [8,31,33]. FITC-
albumin has advantages as inert vehicle [26] and is
comparable with FITC-dextran regarding molecular struc-
ture, which revealed significant associations to infarct size
and impaired neuronal structures as shown by Fluoro-Jade
staining [32]. Concerning the time course of BBB impair-
ment basically 2 hypotheses exist: Long-lasting BBB open-
ing (e.g., several weeks) has been reported shortly after
ischemia/reperfusion [31,33], whereas other authors
reported a biphasic dynamics [7,8]. As shown in controls,
total leakage decreased from 5 to 25 hours, whereas the
leakage proportion did not differ between 5 and 25 hours,
Figure 3 Treatment-dependent representative samples of impaired vessels (A) at 5 hours displayed by confocal laser scanning
micrographs (100× magnification; scale bar = 20 μm). Total paravasal leakage (B) of FITC-albumin on ischemic hemisphere considering
background staining as detected on contra-lesional hemisphere and extra-/intravasal ratio (C), calculated by means on affected hemisphere.
Sample size for leakage and ratio at 5 hours (control/NBO/HBO/tPA/HBO+tPA): 8/8/8/7/8, at 25 hours: 8/8/8/8/8. Bars: means, lines: standard
errors, P-value: *<0.05, **<0.01.
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comparison is limited by different types of ischemia, more
precisely, thromboembolic in the present study versus fila-
ment-induced ischemia/reperfusion in previous reports
[7,8,31,33]. Concerning the treatment, the present data
revealed the lowest total leakage for tPA at 5 hours, most
likely related to early recanalization, and tended to an
improved leakage proportion for hyperoxia at 25 hours
indicating BBB stabilization. As expected, use of tPA wor-
sened BBB integrity at 25 hours, while co-administered
HBO showed no attenuation of this effect. The loss of
integrity is mainly attributed to MMP activation due to
enzymatic effects of tPA [21,34], as previously shown by a
tPA dose-dependent correlation of BBB leakage and
MMP-9 levels [20]. Interestingly, the leakage proportion
solely correlated with early functional impairment, indicat-
ing that worsened BBB integrity following tPA and HBO
+tPA were not clinically relevant at 24 hours.
MMPs as proteolytic enzymes known to degrade
extracellular matrix and corresponding TIMPs with pri-
marily inhibiting functions [9,21], were measured to
reveal mechanisms of BBB regulation. Park et al. [35]
demonstrated a significant correlation between MMP-9
values in blood and brain tissue, which enables parallel
serum investigation and brain tissue analysis by immu-
nohistochemistry. Previous studies associated vascular
disruption with MMP-2 [36] and MMP-9 [30,37]. This
becomes relevant in tPA-related hemorrhagic transfor-
mation [22,38], because tPA raises MMPs and TIMPs as
consequence of plasminogen activation [21,34,39]. Prior
studies revealed an inconsistent time course of MMPs,
whereas here MMP-2 levels were found to increase
within hours after ischemia mediating potentially initial
BBB opening, which might be followed by a MMP-9-
related second opening during the first days [9,38,40].
Other authors noted that MMP-9 responses in the acute
phase, and afterwards MMP-2 in later phases after
stroke [10]. These conflicting data may result from dif-
ferent measurement techniques, ischemia models (tran-
sient/permanent) and animal species. Here, the MMP-9
levels at most tended to increase at 5 hours but mark-
edly decreased at 25 hours when compared to sham,
coherent with reports on later peak elevation [9,40].
Overall, HBO led to the lowest MMP-2 levels at
Figure 4 Serum levels of MMP-2 (A), MMP-9 (B), TIMP-1 (C), and TIMP-2 (D), obtained during final narcosis at 5 or 25 hours. Sample
sizes for MMP-2, MMP-9, TIMP-1, and TIMP-2 at 5 hours (sham/control/NBO/HBO/tPA/HBO+tPA): 2/8/8/8/7/8, at 25 hours: 2/8/8/7/8/8. Bars:
means, lines: standard errors, P-value: *<0.05, **<0.01.
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ing the first 25 hours, which is in accordance with low
leakage. Veltkamp et al. [15] also demonstrated a MMP-
9 reduction with corresponding decreased basal lamina
degradation at 24 hours following HBO in experimental
stroke. tPA resulted in an elevated MMP-2 level, but
unexpectedly HBO failed to attenuate this effect with
concomitant use. The data on TIMPs resembled those
of the MMPs: At 25 hours, HBO led to the lowest
values and tPA-associated interventions resulted in
increased TIMPs. Currently, causal links between MMPs
and TIMPs remain unresolved due to different interpre-
tations: TIMPs might be reactively elevated correspond-
ing with MMPs, or following stroke itself even before
MMPs increased, further complicated by known para-
doxic (exactly not only inhibiting) roles of TIMPs
[21,41]. Future stroke studies on MMP modification
should consider the complexity of MMPs acute deleter-
ious effects and their known delayed beneficial actions
in recovery [9,10]. Zhao et al. [42] impressively demon-
strated decreased infarct sizes by inhibition of MMP at
day 1, but infarct worsening by inhibition at day 7.
T h ep r e s e n ts t u d yh a ss o m el i m itations: Intracerebral
hemorrhage or recanalization rates were not determined,
but complications were considered in mortality and
functional impairment. The 24-hour observation period
limits generalization and implies further research on
BBB integrity during longer periods. Due to the exis-
tence of previous reports regarding NBO simultaneously
applied to tPA [28], this combination has not been
investigated, although it would be easily to implement
into clinical routine. HBO was performed only at 2.4
ATA; a higher pressure would possibly stabilize BBB
integrity, even when co-administered with tPA.
Conclusions
In summary, NBO showed promising results with
decreased functional impairment and reduced BBB per-
meability during the first 25 hours after acute experi-
mental stroke. Surprisingly, HBO failed to demonstrate
functional improvement, but tended to stabilize BBB
and to reduce MMP activation. Concomitant treatment
with HBO and tPA provided early functional improve-
ment, potentially due to enhanced recanalization, but
caused increased BBB permeability and MMP-2 activa-
tion, which could impede delayed regenerative pro-
cesses. Further studies are required to identify long-term
interactions of tPA with both NBO and HBO, especially
in order to avoid unfavorable courses of combined treat-
ment. Additionally, different duration and altered pres-
sure of oxygen application together with tPA need to be
addressed in future studies to explore potential time-
and pressure-related side effects.
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